Browsing Tag
Centers for Medicare & Medicaid Services
10 posts
Apex Infusion targets its next growth phase as SkyKnight Capital enters the infusion market
The private equity partnership gives Apex Infusion additional backing to expand its California home and ambulatory infusion network, but sustainable growth will depend on payer access, clinical capacity and disciplined execution.
Craneware (AIM: CRW) crashes 26% as 340B delays reset the FY27 growth and valuation case
Craneware lost 26% after 340B delays erased FY26 growth. September results must show whether deferred contracts can revive FY27 earnings.
Medicare GLP-1 Bridge launches July 1: $50/month Wegovy, Foundayo, Zepbound covered
Medicare GLP-1 Bridge starts today at $50/month. Wegovy, Zepbound KwikPen and Foundayo are in; Ozempic and Mounjaro are out. Novo and Lilly split the win.
Could Cognizant’s TriZetto Unify AI agent strategy reshape prior authorization in U.S. healthcare?
Could Cognizant’s TriZetto Unify AI strategy transform prior authorization and healthcare automation? Discover what it means for investors and providers.
Can Harbor Health’s Rippl deal redefine dementia care economics in Texas and beyond?
Harbor Health acquires Rippl to expand dementia care and strengthen its pay-vider model. Discover what this means for Texas healthcare markets.
Can UnitedHealth bounce back after CMS’s reimbursement shock blindsides investors?
UnitedHealth’s stock plunge after CMS’s Medicare rate proposal has rattled markets. Find out what triggered the selloff and what’s next for UNH.
CMS LCD withdrawal gives Kerecis fish-skin platform a strategic edge in outpatient wound care reimbursement
CMS pulled back LCD restrictions on wound grafts. Find out how Kerecis' fish-skin platform is gaining a strategic edge as reimbursement reforms unfold.
Can reimbursement unlock the next wave of office-based cancer care? What ZUSDURI and CMS J-codes reveal about oncology’s outpatient shift
Can J-codes like ZUSDURI’s drive the next wave of office-based cancer care? Find out why 2026 could be a turning point in outpatient oncology.
Medicare Advantage faces first enrollment decline in a decade—are UnitedHealth and Humana ready?
Medicare Advantage enrollment may fall by nearly 1 million in 2026. Find out why this shift matters for insurers, investors, and seniors.
Guardant Health’s Shield blood test gains ADLT status, strengthening Medicare coverage for colorectal cancer screening
Guardant Health, Inc. has received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid…